“The company told The Post that it decided during its three years of internal reviews that Enbrel did not show promise for Alzheimer’s prevention because the drug does not directly reach brain tissue. It deemed the likelihood of a successful clinical trial to be low. A synopsis of its statistical findings prepared for outside publication, it says, did not meet its ‘rigorous scientific standards.'” WaPo with an interesting look at one drug non-trial, and how it reflects on the way we develop drugs. Pfizer had clues its blockbuster drug could prevent Alzheimer’s. Why didn’t it tell the world?

+ From underselling a drug to overselling one… NBC News: Ohio doctor charged with 25 counts of murder, accused of prescribing excessive doses of painkillers. “The patient deaths exposed a stunning case of medical oversight and alleged medical malpractice, and called into question how repeated failures potentially involving 30 or more employees could have gone unchecked for so long.”